A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Goserelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 22 Feb 2018 Status changed from not yet recruiting to recruiting.
- 06 Oct 2016 New trial record
- 02 Sep 2016 This trial has been approved by United States Food and Drug Administration (USFDA), as reported by a Luye Pharma Group media release.